Who is sponsoring NCT03685071?

NCT03685071 is sponsored by Assiut University.

What drugs are being tested in NCT03685071?

Interventions in NCT03685071: role of CBC as prognostic tool in sepsis..

What condition does NCT03685071 study?

NCT03685071 studies Infection Systemic.

Is NCT03685071 still recruiting?

NCT03685071 is currently status unknown. Last updated 26 September 2018.

Last reviewed 2018-09-26 · How we verify

NCT03685071

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Value of Complete Blood Count in Severe Infections

Status unknown Last updated 26 September 2018

What this trial tests

trial testing role of CBC as prognostic tool in sepsis. in Infection Systemic in 100 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
30 November 2019

1 June 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2018
Primary completion	30 November 2019
Estimated completion	1 June 2020

Drugs / interventions tested

role of CBC as prognostic tool in sepsis.

Conditions studied

Infection Systemic — all drugs for Infection Systemic →

Sponsor

Assiut University

Who can join

Adults 30 Days to 18, any sex, with Infection Systemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis is a leading cause of hospitalization in pediatric intensive care units, In the last decade, a series of initiatives were implemented that aim not only to improve the understanding of sepsis and the clarity of concepts related to this condition but also to reduce morbidity and mortality due to sepsis through earlier diagnosis and initiation of antibiotic therapy as well as through the provision of specific guidelines for the treatment of pediatric sepsis. Despite these measures and the lower mortality from sepsis in children compared to adult patients, the impact of sepsis in the pediatric population remains high.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03685071 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 26 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03685071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing